Sable Bio
An innovative B2B software startup changing how biotech and pharma companies evaluate drug target safety for effective decision-making
Sable Bio has raised €4.9M across 2 funding rounds from 4 investors, most recently a Seed round in Feb 2026. Based in London, UK; active in Software. Data as of 28 Oct 2026.
London, UKsablebio.com ↗
Total raised
€4.9M
€4,900,000
Funding rounds
2
Investors
4
distinct backers
Active since
2024-02
latest 2026-02
Funding by year
EUR raised per year · 2026 YTDSable Bio — funding by year — interactive chart.
Data table
| Sable Bio — funding by year | |
|---|---|
| 2024 | €1.7M |
| 2026 | €3.2M |
Signals
High confidenceRaise-next likelihood61
base rate 44% for Seed
- ▲ In typical raise window
- ▲ Up-round momentum
Exit likelihood13
base rate 11% (2+ rounds)
- ▼ Young (<3y)
- ▲ Recently backed by strong-exit-track investors
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-02-11 | Seed | €3.2M | Episode 1,MMC Ventures,Seedcamp | View deal → |
| 2024-02-06 | Pre-Seed | €1.7M | Episode 1,Seedcamp | View deal → |